Ergoteles LLC Denali Therapeutics Inc. Transaction History

Ergoteles LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$23.37 - $32.96 $624,049 - $880,130	-26,703 Reduced 71.23%	10,788 $318,000
Q1 2023 May 10, 2023	BUY	$21.91 - $32.67 $821,427 - $1.22 Million	37,491 New	37,491 $863,000
Q2 2022 Aug 12, 2022	SELL	$20.88 - $35.19 $139,749 - $235,526	-6,693 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$29.0 - $47.27 $194,097 - $316,378	6,693 New	6,693 $215,000
Q2 2021 Aug 12, 2021	SELL	$50.3 - $78.44 $518,089 - $807,932	-10,300 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$53.8 - $81.53 $554,140 - $839,759	10,300 New	10,300 $588,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.13B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.